Selected studies on the treatment of adult patients with NK/T-cell lymphomas
| Disease . | No. . | Treatment . | . | . | . | . | Adverse effects . | |||
|---|---|---|---|---|---|---|---|---|---|---|
| ORR . | CR . | OS . | PFS . | Mucositis . | Leucopenia . | TRM . | Reference . | |||
| Relapsed/refractory | 19 | AspaMetDex | 78% | 61% | 2 y: 40% | 2 y: 40% | NR | Grade 3/4: 44% | 0% | 16 |
| Newly diagnosed, relapsed/refractory, any stage | 87 | SMILE ± sandwiched RT (50 Gy) | 81% | 66% | 5 y 50% | 4 y DFS: 64% | NR | Grade 3/4: 67% | 5.7% | 24 |
| Newly diagnosed, stage I/II nasal | 18 | RT (median 50 Gy) | 78% | 78% | 5 y: 30% | 5 y: 30.5% | NR | NR | NR | 51 |
| Newly diagnosed, stage I/II nasal | 31 | RT (median 50 Gy) | 100% | 97% | 5 y: 66% | 5 y: 61% | NR | NR | NR | 52 |
| Newly diagnosed, stage I/II nasal | 17 | CHOP + RT (45 Gy) | 58% | 58% | 3 y: 59% | NR | NR | NR | NR | 54 |
| Newly diagnosed, stage I/II nasal | 27 | Concurrent RT (50 Gy) + 2/3DeVIC | 81% | 77% | 2 y: 78% | 2 y: 67% | Grade 3/4: 30% | Grade 3/4: 93% | 0% | 56 |
| Newly diagnosed, stage I/II nasal | 30 | Concurrent RT (40 Gy) + cisplatin + VIPD | 83% | 80% | 3 y: 86% | 3 y: 85% | Grade 1/2: 11% | Grade 3/4: 14% | 6.6% | 57 |
| Newly diagnosed, stage I/II nasal | 26 | LVP + sandwich RT (56 Gy) | 89% | 81% | 2 y: 89% | 2 y: 81% | Grade 3: 23% | Grade 3: 3% | 0% | 59 |
| Newly diagnosed, stage I/II nasal | 27 | GELOX + sandwiched RT (56 Gy) | 96% | 74% | 2 y: 86% | 2 y: 86% | Grade 3: 15% | Grade 3/4: 33.3% | 0% | 60 |
| Newly diagnosed, stage IV, or relapsed/refractory | 38 | SMILE | 79% | 45% | 1 y: 55% | 1 y: 53% | NR | Grade 3/4: 100% | 5.3% | 62 |
| Disease . | No. . | Treatment . | . | . | . | . | Adverse effects . | |||
|---|---|---|---|---|---|---|---|---|---|---|
| ORR . | CR . | OS . | PFS . | Mucositis . | Leucopenia . | TRM . | Reference . | |||
| Relapsed/refractory | 19 | AspaMetDex | 78% | 61% | 2 y: 40% | 2 y: 40% | NR | Grade 3/4: 44% | 0% | 16 |
| Newly diagnosed, relapsed/refractory, any stage | 87 | SMILE ± sandwiched RT (50 Gy) | 81% | 66% | 5 y 50% | 4 y DFS: 64% | NR | Grade 3/4: 67% | 5.7% | 24 |
| Newly diagnosed, stage I/II nasal | 18 | RT (median 50 Gy) | 78% | 78% | 5 y: 30% | 5 y: 30.5% | NR | NR | NR | 51 |
| Newly diagnosed, stage I/II nasal | 31 | RT (median 50 Gy) | 100% | 97% | 5 y: 66% | 5 y: 61% | NR | NR | NR | 52 |
| Newly diagnosed, stage I/II nasal | 17 | CHOP + RT (45 Gy) | 58% | 58% | 3 y: 59% | NR | NR | NR | NR | 54 |
| Newly diagnosed, stage I/II nasal | 27 | Concurrent RT (50 Gy) + 2/3DeVIC | 81% | 77% | 2 y: 78% | 2 y: 67% | Grade 3/4: 30% | Grade 3/4: 93% | 0% | 56 |
| Newly diagnosed, stage I/II nasal | 30 | Concurrent RT (40 Gy) + cisplatin + VIPD | 83% | 80% | 3 y: 86% | 3 y: 85% | Grade 1/2: 11% | Grade 3/4: 14% | 6.6% | 57 |
| Newly diagnosed, stage I/II nasal | 26 | LVP + sandwich RT (56 Gy) | 89% | 81% | 2 y: 89% | 2 y: 81% | Grade 3: 23% | Grade 3: 3% | 0% | 59 |
| Newly diagnosed, stage I/II nasal | 27 | GELOX + sandwiched RT (56 Gy) | 96% | 74% | 2 y: 86% | 2 y: 86% | Grade 3: 15% | Grade 3/4: 33.3% | 0% | 60 |
| Newly diagnosed, stage IV, or relapsed/refractory | 38 | SMILE | 79% | 45% | 1 y: 55% | 1 y: 53% | NR | Grade 3/4: 100% | 5.3% | 62 |
For a list of the regimens, please refer to Table 1.
DFS, disease-free survival; No., number of patients; NR, not reported; RT, radiotherapy.